ReviewHypertension (Dallas, Tex. : 1979)2024
Immune Mechanisms in Hypertension.
Review in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Association between systemic inflammation and long-term mortality in emergency department patients with severe hypertension.Clinics (Sao Paulo, Brazil) · 2026Article
- Review
- Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases.Pharmacological reviews · 2026Review
- Article
- B1a Cell-IgM Axis Protects Against Hypertension by Blunting IFNγ+CD4+T Cells.Circulation research · 2026Article
- LL-37 IgG levels are associated with clinical characteristics and T follicular cell response in acute coronary syndrome in adults.Physiological reports · 2026Article
- Role of autonomic receptors in ethyl ferulate-induced cardiovascular effects in normotensive and hypertensive female rats.Pflugers Archiv : European journal of physiology · 2026Article
- Integrative network pharmacology and experimental study of Qingda granule in hypertension-induced endothelial dysfunction.Experimental animals · 2026Article
- The 129S1/SvlmJ mouse strain recapitulates severe hypertensive target organ damage under moderate angiotensin II-induced hypertension.Scientific reports · 2026Article
- The relationship between white blood cell counts and pediatric hypertension: a prospective cohort study.Journal of human hypertension · 2026Article
- Ablation ofScience (New York, N.Y.) · 2026Article
- Mean arterial pressure is not associated with type 2 diabetes mellitus in Japan: a secondary retrospective analysis.BMC endocrine disorders · 2026Article
- The neuro-immune axis in preeclampsia: from the maternal-fetal interface to systemic dysregulation.Frontiers in immunology · 2026Review
- Neural-immune-cardiovascular axis: from mechanistic crosstalk to therapeutic targets in cardiovascular disease.Frontiers in immunology · 2026Review
- The Physiological Roles and Pathological Implications of Urea Transporters in the Cardiovascular System.Biomedicines · 2025Review
- Effect of dietary fiber intake on blood pressure control in type 2 diabetic patients in selected hospitals of Ethiopia.Scientific reports · 2025Article
- Uncovering immune pathways for therapeutic targeting of hypertension.Expert opinion on therapeutic targets · 2025Review
- Article
- The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications.Signal transduction and targeted therapy · 2025Review
- Connection between Impaired Fasting Glucose or Type 2 Diabetes Mellitus and Sepsis: A 10-Year Observational Data from the National Health Screening Cohort.Diabetes & metabolism journal · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
It is now apparent that immune mediators including complement, cytokines, and cells of the innate and adaptive immune system contribute not only to blood pressure elevation but also to the target organ damage that occurs in response to stimuli like high salt, aldosterone, angiotensin II, and sympathetic outflow. Alterations of vascular hemodynamic factors, including microvascular pulsatility and shear forces, lead to vascular release of mediators that affect myeloid cells to become potent antigen-presenting cells and promote T-cell activation. Research in the past 2 decades has defined specific biochemical and molecular pathways that are engaged by these stimuli and an emerging paradigm is these not only lead to immune activation, but that products of immune cells, including cytokines, reactive oxygen species, and metalloproteinases act on target cells to further raise blood pressure in a feed-forward fashion. In this review, we will discuss these molecular and pathophysiological events and discuss clinical interventions that might prove effective in quelling this inflammatory process in hypertension and related cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.